Таргетные препараты во второй линии противоопухолевой терапии диссеминированного колоректального рака
https://doi.org/10.21518/2079-701X-2015-8-91-92
Аннотация
В течение многих лет колоректальный рак является одним из наиболее распространенных видов злокачественных опухолей в мире. При этом результаты лечения больных метастатическим колоректаль-ным раком на протяжении длительного времени оставались неудовлетворительными. Существенное влияние на улучшение отдаленных результатов лечения больных с метастазами колоректального рака оказало развитие таргетной терапии. В статье изложены основные рекомендации по использованию таргетных препаратов во второй линии терапии диссеминированного колоректального рака, описан механизм действия, эффективность, токсичность, особенности применения. Приведены данные по новым таргетным препаратам, проходящим этап изучения в рамках клинических исследований.
Об авторах
К. А. Воронцова
Российский онкологический научный центр им. Н.Н. Блохина, Москва
Россия
Россия
Е. В. Черноглазова
Российский онкологический научный центр им. Н.Н. Блохина, Москва
Россия
Россия
Г. В. Вышинская
Российский онкологический научный центр им. Н.Н. Блохина, Москва
Россия
Россия
Список литературы
1. HickLin DJ, ELLis LM. Role of the vascular endothelial growth factor pathway in the tumor growth and angiogenesis. J. Clin Oncol., 2005; 23: 1011-27.
2. Shibuya M, Claesson-Welsh L. Signal transduction by VEGF receptors in regulation of angio-genesis and lymphangiogenesis. Exp Cell Res, 2006; 312: 549-60.
3. Giantonio B, Catalano P, Meropol N et al. Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200 J. Clin. Oncol., 2007. 20. 1539 1544.
4. Kabbinavar F, Hurwitz HI, Fehrenbacher L et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer J. Clin. Oncol., 2003. 21. 60.
5. Jaafar Bennouna, Javier Sastre, Dirk Arnold et al., on behalf of the ML18147 Study Investigators. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. The LANCET Oncology, 2013, 14, 1: 29-37.
6. Osterlund P, Alonso-Orduna V, Schlichting C et al. Bevacizumab plus chemotherapy beyond first progression in patients with metastatic colorectal cancer (mCRC) previously treated with first-line bevacizumab plus chemotherapy (ML18147): Efficacy and safety analyses by oxaliplatin vs irinotecan-based CT. Ann Oncol., 2012; 23(Suppl 9): ix195.
7. Masi G, Salvatore L, Boni L et al, on behalf of the BEBYP Study Investigators. Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: final results of the randomized BEBYP trial. Ann Oncol., 2015 Jan 18. pii: mdv012.
8. Holash J, Davis S, Papadopoulos N et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci U S A. 2002 Aug 20;99(17):11393-8. Epub 2002 Aug 12.
9. Patricia A Tang, Steven J Cohen, Christian Kollmannsberger et al. Phase II Clinical and Pharmacokinetic Study of Aflibercept in Patients with Previously Treated Metastatic Colorectal Cancer. Clin Cancer Res, November 1, 2012, 18; 6023.
10. Tang SJ, Cohen GA. Bjarnason et al. Phase II trial of aflibercept (VEGF Trap) in previously treated patients with metastatic colorectal cancer (MCRC): A PMH phase II consortium trial. J Clin Oncol (Meeting Abstracts) May 2008, 26, 15 4027.
11. Van Cutsem E, Tabernero J, Lakomy R. Intravenous aflibercept versus placebo in combination with irinotecan/5-FU (FOLFIRI) for second-line treatment of metastatic colorectal cancer (MCRC): results of a multinational Phase III trial (EFC10262-VELOUR) Ann Oncol. 2011; 22.
12. Van Cutsem E, Tabernero J, Lakomy R et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol 2012; 30(28): 3499-506.
13. Paul Ruff, David R Ferry, Radek Lakomy et al. Time course of safety and efficacy of afliber-cept in combination with FOLFIRI in patients with metastatic colorectal cancer who progressed on previous oxaliplatin-based therapy. European Journal of Cancer (2015) 51, 18-26.
14. David Raymond Ferry, Alberto F. Sobrero, Roberto Bordonaro et al. Ziv-aflibercept (Z) in combination with FOLFIRI for second-line treatment of patients (pts) with metastatic colorectal cancer (mCRC): Interim safety data from the global aflibercept safety and quality-of-life program in pts pretreated with bevacizumab (B). J Clin Oncol (Meeting Abstracts) January 2014 32 3, 556.
15. Roberto Bordonaro, Alberto F. Sobrero, Luca Frassineti et al. Ziv-aflibercept in combination with FOLFIRI for second-line treatment of patients with metastatic colorectal cancer (mCRC): Interim safety data from the global aflibercept safety and quality-of-life program (ASOoP and AFEOT studies) in patients ?65. J Clin Oncol (Meeting Abstracts) January 2014 32 3, 545.
16. Josep Tabernero, Allen Lee Cohn, Radka Obermannova et al. and The RAISE Study Investigators. RAISE: A randomized, double-blind, multicenter phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab (RAM) or placebo (PBO) in patients (pts) with metastatic colorectal carcinoma (CRC) progressive during or following first-line combination therapy with bevacizumab (bev), oxalipl-atin (ox), and a fluoropyrimidine (fp). J Clin Oncol (Meeting Abstracts) January 2015 33 3, 512.
17. Howard S Hochster, Paul J Catalano, Edith P Mitchell et al. E7208: A randomized phase II trial of irinotecan and cetuximab (IC) versus IC plus ramucirumab (ICR) in second line therapy of KRAS wild type colorectal cancer (CRC). J Clin Oncol (Meeting Abstracts) January 2015 33 3 TPS793.
18. Peeters M, Strickland AH, Lichinitser M et al. A randomised, double-blind, placebo-controlled phase 2 study of trebananib (AMG 386) in combination with FOLFIRI in patients with previously treated metastatic colorectal carcinoma BrJ Cancer. 2013 Feb 19; 108(3): 503-511.
19. Thomas Hoehler, Thomas Decker, Christoph Schimanski et al. Final results of the AIO 0307 study: A controlled, randomized, double-blind phase II study of FOLFOX6 or FOLFIRI combined with sorafenib (S) versus placebo (P) in second-linemetastatic colorectal carcinoma (mCRC) treatment. J Clin Oncol (Meeting Abstracts) May 2013 31 15_suppl 3586.
20. Goldstein Ni, Prewett M, Zuklys K et al. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xeno-graft model. Clin. Cancer Res. 1995, 1: 1311-1318.
21. Vallbohmer D, Zhang W, Gordon M et al. Molecular determinants of cetuximab efficacy. J. Clin. Oncol. 2005, 23: 3536: 3544.
22. Segaert S, Van Cutsem E: Clinical signs, patho-physiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann. Oncol. 2005, 16: 1425-1433.
23. Cunningham D, Humblet Y, Siena S et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinitecan-refractory metastatic colorectal cancer. N. Engl. J. Med. (2004) 351(4):337-345.
24. Robert C, Soria JC, Spatz A et al. Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol. 2005, 6: 491-500.
25. Schrag D, Chung KY, Flombaum C et al. Cetuximab therapy and symptomatic hypomagnesemia. J. Natl. Cancer Inst. (2005) 97(16): 1221-1810.
Рецензия
Для цитирования:
Воронцова КА, Черноглазова ЕВ, Вышинская ГВ. Таргетные препараты во второй линии противоопухолевой терапии диссеминированного колоректального рака. Медицинский Совет. 2015;(8):91-92. https://doi.org/10.21518/2079-701X-2015-8-91-92
For citation:
Vorontsova KA, Chernoglazova EV, Vyshinskaya GV. Targeted drugs in the second line anticancer therapy of disseminated colorectal cancer. Meditsinskiy sovet = Medical Council. 2015;(8):91-92. (In Russ.) https://doi.org/10.21518/2079-701X-2015-8-91-92
Просмотров:
343
Послать статью по эл. почте 